

Bassianolone: an antimicrobial precursor of cephalosporolides E and F from the entomoparasitic fungus *Beauveria bassiana*

Juan L. Oller-López,^a María Iranzo,^b Salvador Mormeneo,^b Eulalia Oliver,^a Juan M. Cuerva^a and J. Enrique Oltra^{*a}


^a Department of Organic Chemistry, Institute of Biotechnology, Faculty of Sciences, E-18071, Granada, Spain. E-mail: joltra@ugr.es; Fax: 34 958 248437; Tel: 34 958 248091

^b Department of Microbiology, Faculty of Pharmacy, E-46100, Burjassot, Valencia, Spain. E-mail: maria.iranzo@uv.es; Fax: 34 963 544682; Tel: 34 963 543025

Received 25th November 2004, Accepted 18th February 2005
First published as an Advance Article on the web 25th February 2005

We have established the chemical structure of (+)-bassianolone (3), the antimicrobial compound precursor of cephalosporolides E and F, and that of the furan metabolite 4 from the entomopathogenic fungus *Beauveria bassiana*.


In 1985, Hanson and co-workers isolated two rare metabolites, cephalosporolides E (1) and F (2), from an industrial fermentation of the fungus *Cephalosporium aphidicola* grown under sulfur limiting conditions.¹ The authors established the chemical structure of compounds 1 and 2 with the aid of X-ray analysis and suggested that these products might arise from another fungal metabolite, cephalosporolide C, via a process involving hydrolysis, relactonization and acetal formation.¹ Nevertheless, they could not mimic this process in the laboratory. Intriguingly, cephalosporolides E and F were (to date) never again detected in nature, despite intense research devoted to fungal secondary metabolism in recent years.^{2–5}



Within our programme to investigate the biotechnological use of fungi,^{6–8} we recently became interested in the metabolites produced under stressful conditions by *Beauveria bassiana*, an entomoparasitic deuteromycete⁹ which has found wide application as a whole-cell biocatalyst.^{10,11} Among the products excreted by this fungus to the broth culture of a low-nitrogen medium,⁶ we unexpectedly¹² found cephalosporolides 1¹³ and 2,¹⁴ together with a third metabolite of a previously unknown chemical structure, which we called (+)-bassianolone (3),¹⁵ and a new furan metabolite 4, apparently derived from the same biogenetic pathway as 3.


The HRMS of 3 indicated a C₁₀H₁₆O₅ molecular formula corresponding to three double-bond equivalents, whereas its ¹³C NMR spectrum showed only two signals of sp² carbons, assignable to γ -lactone (169.6 ppm) and ketone (214.4 ppm) groups, thus revealing the monocyclic nature of this fungal metabolite. To find out more about its structure, 3 was treated with acetic anhydride and pyridine, thus obtaining acetyl derivative 5.¹⁶ The ¹H NMR spectrum of 5 showed two acetate-group signals (2.02 and 2.04 ppm) together with a methyl doublet (10-H₃) with a chemical shift (1.28 ppm) indicating that the CH₃ group was attached to an oxygenated carbon. Moreover, three proton signals at 5.05 (9-H) and 5.45 (3-H) and 5.16 ppm (4-H) revealed the positions of the two acetate groups and the closure of the γ -lactone ring respectively. The COSY spectrum showed three bond correlations between 2-H and 3-H, 3-H and 4-H, and 4-H and 5-H, which were confirmed by analysis of the coupling-constant values in the ¹H NMR spectrum. Furthermore, correlations between 7-H and 8-H, 8-H and 9-H, and 9-H and 10-H were also observed in the COSY

spectrum. Moreover, the HMBC spectrum showed long-range heteronuclear correlations between 1-C and 2-H, and between 6-C and 5-H and 7-H, definitively establishing the carbon skeleton of 5 and consequently that of 3. The relatively high value of the coupling constant $J_{3,4}$ (10 Hz) suggested a *cis*-disubstitution pattern for the γ -lactone ring.¹⁷ This stereochemistry, together with the 9*R** relative configuration of 3, were subsequently confirmed by chemical correlation with 1 and 2 (see below).




We then determined the structures of metabolite 4¹⁸ and its methyl ester 6.¹⁹ The HRMS of 4 revealed a C₁₀H₁₄O₄ molecular formula corresponding to four elements of unsaturation, whereas its ¹³C NMR spectrum showed only four signals assignable to olefin carbons (106, 109, 145.4 and 155.6 ppm) and a carbonyl group (174.3 ppm), thus indicating the monocyclic character of this metabolite. Moreover, the IR spectrum showed a group of bands between 2500 and 3000 cm⁻¹ and carbonyl absorption at 1722 cm⁻¹, characteristic of carboxylic acids. Therefore we treated 4 with diazomethane, obtaining the corresponding ester 6. In the ¹H NMR spectrum, the doublet of a methyl group (10-H₃) attached to an oxygenated CH appeared at 1.27 ppm whereas the multiplicity, coupling constant ($J_{4,5}$ 3 Hz) and chemical shift values (5.97 and 6.13 ppm) of 4-H and 5-H were assignable to a 2,5-disubstituted furan ring,¹⁷ thus finally establishing the structure of 6 and consequently that of 4. We are currently trying to determine the absolute configuration of compounds 1–6.²⁰

When we passed bassianolone (3) through a pad of silica gel we obtained a mixture of spiroketals 1 and 2 (Scheme 1). This result confirms the relative (3*S**, 4*S**, 9*R**) configuration of bassianolone and suggests that, in contrast with Hanson's proposal,¹ it is the true chemical parent of cephalosporolides E and F, which are possibly simple artefacts formed during



Scheme 1 Silica-promoted spirocyclization of 3.

the isolation process. Moreover, the co-occurrence of **3** and **4** in *B. bassiana* suggests the existence of a common biogenetic precursor, probably of short lifetime, which we have called pre-bassianolone (**7**). This metabolic intermediate, containing an even number of carbon atoms, might derive from the polyketide pathway and might also be the precursor of cephalosporolide C (**8**) and related metabolites from *C. aphidicola*¹ (Scheme 2).



Scheme 2 Proposed biogenesis of **3**, **4** and **8** from pre-bassianolone (**7**).

Cases of a common biogenetic precursor for diverse metabolites are numerous²¹ and probably constitute one of the devices employed by nature to reduce the number of genes required for the biosynthesis of natural products.²²

Finally, we tested the *in vitro* antimicrobial activity²³ of compounds **1–4** (100 µg ml⁻¹) against gram-positive (*Bacillus megaterium* and *Staphylococcus aureus*), gram-negative (*Escherichia coli* and *Pseudomonas aeruginosa*) and fungal (*Candida albicans*) species. Cephalosporolides E and F, and the furan metabolite **4** showed no antimicrobial activity, whilst (+)-bassianolone (**3**) completely inhibited the visible growth of *S. aureus* and *C. albicans*. Therefore, we subsequently centred our attention on **3**, which also blocked the growth of *Staphylococcus epidermidis*, *Streptococcus pyogenes*, *Micrococcus luteus*, *Mucor rouxii* and *Schizosaccharomyces pombe*, and drastically reduced the growth of *Saccharomyces cerevisiae* and *Yarrowia lipolytica*.

In summary, we have established the chemical structures of (+)-bassianolone (**3**) and the furan derivative **4**, two unprecedented metabolites from the fungus *B. bassiana*. Bassianolone has proved to be the true precursor of cephalosporolides E (**1**) and F (**2**) and showed selective antimicrobial activity against gram-positive cocci and fungi. The antimicrobial activity of bassianolone requires further studies and, as there is a clinical need for novel antibacterial²⁴ and antifungal²⁵ drugs, we are currently engaged in the chemical synthesis of **3** in order to obtain enough product to complete its biological analysis.

Acknowledgements

To the "Junta de Andalucía" for the financial support (PAI group FQM339), to the Spanish "Ministerio de Educación Cultura y Deporte" for the grant provided to J.L.O.-L., to Dr. J. Avalos (University of Sevilla) for the *B. bassiana* species and to our English colleague Dr. J. Trout for revising our English text.

References

- M. J. Ackland, J. R. Hanson, P. B. Hitchcock and A. H. Ratcliffe, *J. Chem. Soc., Perkin Trans. 1*, 1985, 843.
- T. S. Bugni and C. M. Ireland, *Nat. Prod. Rep.*, 2004, **21**, 143.

- R. J. Cole, M. A. Schweikert and B. B. Jarvis, *Handbook of Secondary Fungal Metabolites*, vol. 1–3, Academic Press, San Diego 2003.
- M. Gill, *Nat. Prod. Rep.*, 2003, **20**, 615 and previous issues in this series.
- J. B. Gloer, *Acc. Chem. Res.*, 1995, **28**, 343.
- J. L. Oller-López, J. Avalos, A. F. Barrero and J. E. Oltra, *Appl. Microbiol. Biotechnol.*, 2003, **63**, 282 and references therein.
- A. F. Barrero, J. E. Oltra, J. Robinson, P. V. Burke, D. Jiménez and E. Oliver, *Steroids*, 2002, **67**, 403.
- J. Malmström, C. Christophersen, A. F. Barrero, J. E. Oltra, J. Justicia and A. Rosales, *J. Nat. Prod.*, 2002, **65**, 364.
- N. Nikoh and T. Fukatsu, *Mol. Biol. Evol.*, 2000, **17**, 629.
- G. Haufe, D. Wölker and R. Fröhlich, *J. Org. Chem.*, 2002, **67**, 3022.
- H. L. Holland, T. A. Morris, P. J. Nava and M. Zabic, *Tetrahedron*, 1999, **55**, 7441.
- For previously described metabolites from this fungus, see: H. Kikuchi, N. Takahashi and Y. Oshima, *Tetrahedron Lett.*, 2004, **45**, 367 and references therein.
- Spectroscopic properties, including optical rotation, of product **1** isolated from the broth culture of *B. bassiana* were in accordance with those reported for (+)-cephalosporolide E excreted by *C. aphidicola*¹.
- Compound **2** from *B. bassiana*: golden syrup; [α]_D²⁵ = -33.3 (c 0.79 in CHCl₃); IR, ¹H and ¹³C NMR, and mass spectra were in accordance with those reported for cephalosporolide F from *C. aphidicola*¹.
- Data for **3**: white powder; mp = 82–84 °C; [α]_D²⁵ = +97.0 (c 2.70 in MeOH); δ _C (100 MHz, CDCl₃) 19.4 (q), 33.7 (t), 38.9 (t), 47.0 (t), 43.4 (t), 68.8 (d), 72.1 (d), 75.0 (d), 169.6 (s), 214.4 (s); m/z (FAB) 239.0897 [M + Na]⁺ (C₁₀H₁₆O₅Na requires 239.0895).
- Data for **5**: golden syrup; δ _H (400 MHz, CDCl₃) 1.28 (3 H, d, *J*_{10,9} 6, 10-H), 2.02 (3 H, s, CH₃CO), 2.04 (3 H, s, CH₃CO), 2.35 (2 H, m, 7-H), 2.57 (1 H, dd, *J*_{2a,3} 12, *J*_{gem} 17, 2-Ha), 2.67 (1 H, dd, *J*_{5a,4} 3, *J*_{gem} 18, 5-Ha), 2.81 (1 H, dd, *J*_{2b,3} 3, *J*_{gem} 17, 2-Hb), 3.02 (1 H, dd, *J*_{5b,4} 7, *J*_{gem} 18, 5-Hb), 5.05 (1 H, m, 9-H), 5.16 (1 H, ddd, *J*_{4,5a} 3, *J*_{4,5b} 7, *J*_{4,3} 10, 4-H), 5.45 (1 H, ddd, *J*_{3,2b} 3, *J*_{3,4} 10, *J*_{3,2a} 12, 3-H); δ _C (100 MHz, CDCl₃) 19.7 (C-10), 20.9 (CH₃CO), 21.0 (CH₃CO), 33.4 (C-8), 38.2 (C-2), 40.0 (C-7), 43.5 (C-5), 68.7 (C-3), 71.0 (C-4), 72.6 (C-9), 167.9 (C-1), 169.7 (CH₃CO), 170.2 (CH₃CO), 206.7 (C-6). NMR peak assignments were made with the aid of 2D NMR experiments (COSY, HMQC and HMBC). The numbering system follows that employed in ref. 1 for cephalosporolides E and F.
- E. Pretsch, P. Bühlmann and C. Affolter, *Structure Determination of Organic Compounds. Tables of Spectral Data*, 3rd ed., Springer, New York, 2000.
- Spectroscopic data for **4**: IR ν_{\max} /cm⁻¹ 3403 (OH), 2966, 2931, 2635, 1722 (CO), 1561; δ _H (300 MHz, CDCl₃) 1.21 (3 H, d, *J* 6), 1.76 (2 H, q, *J* 6), 2.70 (2 H, m), 3.66 (2 H, s), 3.84 (1 H, sextuplet, *J* 6), 5.94 (1 H, d, *J* 2.5), 6.11 (1 H, d, *J* 2.5); δ _C (75 MHz, CDCl₃) 23.4 (q), 24.4 (t), 33.8 (t), 37.3 (t), 67.5 (d), 106.0 (d), 109.0 (d), 145.4 (s), 155.6 (s), 174.3 (s); m/z (EI) 198.0898 [M]⁺ (C₁₀H₁₄O₄ requires 198.0892).
- Spectroscopic data for **6**: [α]_D²⁵ = +46.0 (c 0.13 in MeOH); δ _H (300 MHz, CDCl₃) 1.27 (3 H, d, *J* 7), 1.80 (2 H, q, *J* 7), 2.74 (2 H, m), 3.67 (2 H, s), 3.80 (3 H, s), 3.86 (1 H, sextuplet, *J* 7), 5.97 (1 H, d, *J* 3), 6.13 (1 H, d, *J* 3); δ _C (75 MHz, CDCl₃) 23.6 (q), 24.5 (t), 34.1 (t), 37.5 (t), 52.3 (q), 67.4 (d), 106.0 (d), 108.7 (d), 145.9 (s), 155.5 (s), 170.2 (s).
- Using X-ray analysis, Hanson and co-workers were able to establish the relative stereochemistry of cephalosporolide E but not the absolute configuration¹.
- The biosynthesis of various families of sesquiterpene lactones with different carbon skeletons (eudesmanolides, guaianolides, elemanolides, etc.) from germacranolides as common precursors is one of the most intriguing examples; for a review including synthesis and biology of sesquiterpene lactones see: H. M. R. Hoffmann and J. Rabe, *Angew. Chem., Int. Ed. Engl.*, 1985, **24**, 94.
- E. Cerdá-Olmedo, *Crit. Rev. Microbiol.*, 1994, **20**, 151.
- National Committee for Clinical Laboratory Standards. Approved standard M7-A2, Villanova, Pa, USA, 1990. Approved standard M27-A, Wayne, Pa, USA, 1997.
- B. Spellberg, J. H. Powers, E. P. Brass, L. G. Miller and J. E. Edwards, *Clin. Infect. Dis.*, 2004, **38**, 1279.
- F. C. Odds, A. J. P. Brown and N. A. R. Gow, *Trends Microbiol.*, 2003, **11**, 272.